A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator Controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
Latest Information Update: 20 Sep 2022
At a glance
- Drugs Brexpiprazole (Primary) ; Antidepressants; Quetiapine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms Delphinus
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 19 Sep 2022 Results of post-hoc analysis (NCT01360645, NCT01360632, NCT02196506 & NCT01727726) assessing the effects of adjunctive brexpiprazole on different symptom clusters in major depressive disorder, published in the Journal of Affective Disorders.
- 01 Oct 2019 Results of pooled analysis assessing the effect of adjunctive brexpiprazole on metabolic parameters and body weight in adults with major depressive disorder using pooled data from 4 short-term studies and 1 long-term extension study (NCT01360645, NCT01360632, NCT02196506, NCT01727726, NCT01360866) published in the Journal of Clinical Psychiatry
- 02 Dec 2018 Results of post-hoc analysis determining the effect of adjunctive brexpiprazole using pooled data from six randomized studies (NCT01360645, NCT01360632, NCT02196506, NCT01727726, NCT00797966, NCT01052077) published in the International Journal of Neuropsychopharmacology